当前位置:
X-MOL 学术
›
Nat. Rev. Gastroenterol. Hepatol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Achieving health equity in liver disease pharmacotherapy
Nature Reviews Gastroenterology & Hepatology ( IF 65.1 ) Pub Date : 2022-05-17 , DOI: 10.1038/s41575-022-00632-8 Ani Kardashian 1 , Lauren D Nephew 2, 3
Nature Reviews Gastroenterology & Hepatology ( IF 65.1 ) Pub Date : 2022-05-17 , DOI: 10.1038/s41575-022-00632-8 Ani Kardashian 1 , Lauren D Nephew 2, 3
Affiliation
New data demonstrate racial and ethnic disparities in access to prescription medications in persons with chronic liver disease in the USA. Here, we discuss potential health equity solutions that address structural and social determinants of health to mitigate liver health inequities in access to liver disease pharmacotherapies.
中文翻译:
实现肝病药物治疗的健康公平
新数据表明,美国慢性肝病患者在获得处方药方面存在种族和民族差异。在这里,我们讨论潜在的健康公平解决方案,解决健康的结构性和社会决定因素,以减轻获得肝病药物治疗方面的肝脏健康不平等。
更新日期:2022-05-19
中文翻译:
实现肝病药物治疗的健康公平
新数据表明,美国慢性肝病患者在获得处方药方面存在种族和民族差异。在这里,我们讨论潜在的健康公平解决方案,解决健康的结构性和社会决定因素,以减轻获得肝病药物治疗方面的肝脏健康不平等。